Sareum Holdings Refocuses Strategy After SRA737 Licensing Termination

Sareum Holdings ( (GB:SAR) ) has shared an update.

Sareum Holdings plc has announced the termination of the licensing agreement for its cancer drug candidate SRA737 by a U.S.-based biopharma company, effective in March 2025. Despite the setback, Sareum remains committed to advancing its pipeline of TYK2/JAK1 inhibitors, particularly focusing on SDC-1801, which is poised for Phase 2 development, thereby signaling a shift in strategic focus towards its in-house projects.

More about Sareum Holdings

Sareum Holdings plc is a biotechnology company based in Cambridge, UK, focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer. It is noted for its work on small molecules that modify the JAK kinase family, with lead candidates like SDC-1801 and SDC-1802, which target TYK2 and JAK1 pathways and have potential applications in treating autoimmune diseases and cancer immunotherapy.

YTD Price Performance: -54.62%

Average Trading Volume: 397,991

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £33.73M

See more insights into SAR stock on TipRanks’ Stock Analysis page.